Ionis Pharmaceuticals has had a rough run so far this year, even as fresh clinical results have put its drug pipeline in the spotlight. With the share price under pressure, the real issue for investor
Novartis AG’s (NYSE:NVS) Phase 3 Lp(a)HORIZON setback carries implications beyond the Swiss drugmaker. Pelacarsen significantly lowered lipoprotein(a), or Lp(a), but failed to produce a statistically
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $100 price target.
Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the hardest-hit names.
The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.
IONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and licensing partner Roche Holdings AG (OTC:RHHBY) on Wednesday shared prespecified interim outcomes from their ongoing Phase 3 IMAgINATION trial of investiga
CARLSBAD, Calif., September 23, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and partner Roche today announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study eval
View interactive chart, options flow, and AI analysis for IONS on Zorveq Finance.
Open IONS Chart & Analysis →